PersonGen is a clinical-stage CAR-T R&D company, providing innovative solutions for the treatment of tumors and autoimmune diseases. Established in 2010, PersonGen is one of the earliest enterprises in China engaged in CAR-T R&D, and supported from top investors, such as Anke Bio, CICC Capital, and Huatai Capital, etc.PersonGen’s industry-leading platforms include the in vivo CAR-T, NKCE, autologous CAR-T, and UCAR-Vδ1T, as well as end-to-end capabilities in plasmid, lentiviral, and CAR-T cell process development and commercial-scale production. 

The leading candidate of PA3-17 injection (autologous CD7-CAR-T) was approved to enter the pivotal phase II clinical trial and received Breakthrough Therapy Designation by NMPA, making it the world's first autologous CD7-CAR-T product to reach the pivotal phase II clinical stage.